Individualizing treatment for patients with nasopharyngeal cancer | Zendy

Hara Wendy | Zendy; Le QuynhThu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Individualizing treatment for patients with nasopharyngeal cancer

Author(s) -

Hara Wendy,

Le QuynhThu

Publication year - 2015

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/cncr.29418

Subject(s) - medicine , biomarker , oncology , chemoradiotherapy , nasopharyngeal cancer , genotype , cancer , prospective cohort study , single nucleotide polymorphism , ercc1 , radiation therapy , nasopharyngeal carcinoma , dna , genetics , gene , dna repair , biology , nucleotide excision repair

In this issue, Dr. Hui and colleagues report the largest multi‐institutional, prospective trial to date validating circulating Epstein‐Barr virus DNA as a prognostic biomarker for patients with nasopharyngeal cancer after chemoradiotherapy. The ERCC1 C118T single nucleotide polymorphism genotype may also be a potential second biomarker for future investigation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research